Janus Henderson Group PLC Has $118,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Janus Henderson Group PLC lessened its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,533 shares of the company's stock after selling 566,851 shares during the quarter. Janus Henderson Group PLC's holdings in Ginkgo Bioworks were worth $118,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Algert Global LLC acquired a new stake in shares of Ginkgo Bioworks in the second quarter valued at about $36,000. Wellington Wealth Strategies LLC. acquired a new stake in Ginkgo Bioworks during the second quarter worth approximately $41,000. Thoroughbred Financial Services LLC acquired a new stake in Ginkgo Bioworks during the second quarter worth approximately $70,000. Pine Valley Investments Ltd Liability Co boosted its holdings in shares of Ginkgo Bioworks by 653.7% in the 2nd quarter. Pine Valley Investments Ltd Liability Co now owns 220,607 shares of the company's stock valued at $74,000 after purchasing an additional 191,336 shares in the last quarter. Finally, North Star Asset Management Inc. boosted its holdings in shares of Ginkgo Bioworks by 162.6% in the 2nd quarter. North Star Asset Management Inc. now owns 231,100 shares of the company's stock valued at $77,000 after purchasing an additional 143,100 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Price Performance

Ginkgo Bioworks stock traded down $0.07 during trading hours on Monday, reaching $9.37. 1,491,614 shares of the company's stock were exchanged, compared to its average volume of 1,163,462. The stock's 50 day moving average price is $8.43. The firm has a market cap of $538.59 million, a price-to-earnings ratio of -0.72 and a beta of 1.17. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.26 and a twelve month high of $75.20.

Analysts Set New Price Targets

DNA has been the topic of a number of research analyst reports. BTIG Research raised their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a report on Friday, August 23rd. TD Cowen raised their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.